Eastman Kodak"After foundering for several years, Eastman...

STOCK WATCH 8

November 27, 1991|By Opinions on stocks offered by investment experts. Compiled by Steve Halpern for Knight Ridder.

Eastman Kodak

"After foundering for several years, Eastman Kodak's (EK, NYSE, around $46) latest restructuring seems to be taking hold," says Wellesley, Mass.-based United & Babson Investment Report.

"Management is determined to turn the company around. We expect the restructuring to have a positive effect on future earnings. The company should post strong profit gains next year as the economy accelerates. The stock is now yields over 4 percent. Based on historical evaluations, the issue appears very attractive."

Hospital Staffing

"Hospital Staffing Services (HSSI, OTC, around $12) provides registered nurses and other health-care professionals to health-care facilities on an interim basis in 22 states," explains Wall Street Digest of Sarasota, Fla.

"Services include recruitment and placement of contract traveling nurses for short-term assignments of eight to 16 weeks or longer. The company also provides consulting, executive services and in-home medical-care services. Current earnings are up 88 percent. Current sales are up 124 percent. This is a great stock to buy."

Pall Corp.

"Pall (PLL, AMEX, around $35), a maker of filters and systems, has long been in international markets," says United & Babson Investment Report of Wellesley, Mass.

"The company first moved into Europe in 1961 and now generates more than half of its revenues overseas. While expansion costs have hurt results, the company has still managed to compile a 20-year record of consecutively higher sales and earnings. Profits should rise some 20 percent to $1.65 a share. The stock is a buy for long-term appreciation."

Johnson & Johnson

"Johnson & Johnson (JNJ, NYSE, around $95) 1991 sales are expected to reach $12.4 billion, with about 52 percent coming from outside the United States," says United & Babson Investment Report of Wellesley, Mass.

"This truly global firm expects to spend almost $1 billion on research this year, with the majority being targeted at the drug division. The firm is also expanding its presence in the laparoscopic market.

Earnings should grow to $4.35 a share this year and another 15 to 20 percent in 1992. Buy."

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.